{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T05:33:37Z","timestamp":1655876017752},"reference-count":38,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0884","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:24:09Z","timestamp":1525253049000},"source":"Crossref","is-referenced-by-count":3,"title":["The Treatment of Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.3238","author":[{"given":"E. Wolfgang","family":"K\u00fchn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2015,12,21]]},"reference":[{"key":"10.3238\/arztebl.2015.0884_ref1","doi-asserted-by":"crossref","unstructured":"Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287\u2013301","DOI":"10.1016\/S0140-6736(07)60601-1"},{"key":"10.3238\/arztebl.2015.0884_ref2","doi-asserted-by":"crossref","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G: Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 2015; 385:1993\u20132002","DOI":"10.1016\/S0140-6736(15)60907-2"},{"key":"10.3238\/arztebl.2015.0884_ref3","unstructured":"Kuehn EW, Walz G: [Autosomal dominant polycystic kidney disease]. Dtsch Arztebl 2007; 104: A3022\u20138."},{"key":"10.3238\/arztebl.2015.0884_ref4","doi-asserted-by":"crossref","unstructured":"Grantham JJ, Torres VE, Chapman AB, et al.: Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122\u201330","DOI":"10.1056\/NEJMoa054341"},{"key":"10.3238\/arztebl.2015.0884_ref5","doi-asserted-by":"crossref","unstructured":"Chapman AB, Bost JE, Torres VE, et al.: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479\u201386","DOI":"10.2215\/CJN.09500911"},{"key":"10.3238\/arztebl.2015.0884_ref6","doi-asserted-by":"crossref","unstructured":"Chapman AB, Devuyst O, Eckardt KU, et al.: Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015; 88: 17\u201327","DOI":"10.1038\/ki.2015.59"},{"key":"10.3238\/arztebl.2015.0884_ref7","doi-asserted-by":"crossref","unstructured":"Bhutani H, Smith V, Rahbari-Oskoui F, et al.: A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 2015; 88: 146\u201351","DOI":"10.1038\/ki.2015.71"},{"key":"10.3238\/arztebl.2015.0884_ref8","doi-asserted-by":"crossref","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, et al.: Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015; 26: 160\u201372","DOI":"10.1681\/ASN.2013101138"},{"key":"10.3238\/arztebl.2015.0884_ref9","doi-asserted-by":"crossref","unstructured":"Petzold K, Gansevoort RT, Ong AC, et al.: Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrol Dial Transplant 2014; 29: 26\u201332","DOI":"10.1093\/ndt\/gfu091"},{"key":"10.3238\/arztebl.2015.0884_ref10","doi-asserted-by":"crossref","unstructured":"Hildebrandt F, Benzing T, Katsanis N: Ciliopathies. N Engl J Med 2011; 364: 1533\u201343","DOI":"10.1056\/NEJMra1010172"},{"key":"10.3238\/arztebl.2015.0884_ref11","doi-asserted-by":"crossref","unstructured":"Fischer E, Legue E, Doyen A, et al.: Defective planar cell polarity in polycystic kidney disease. Nat Genet 2006; 38: 21\u20133","DOI":"10.1038\/ng1701"},{"key":"10.3238\/arztebl.2015.0884_ref12","doi-asserted-by":"crossref","unstructured":"Lienkamp SS, Liu K, Karner CM, et al.: Vertebrate kidney tubules elongate using a planar cell polarity-dependent, rosette-based mechanism of convergent extension. Nat Genet 2012; 44: 1382\u20137","DOI":"10.1038\/ng.2452"},{"key":"10.3238\/arztebl.2015.0884_ref13","doi-asserted-by":"crossref","unstructured":"Ibraghimov-Beskrovnaya O, Natoli TA: mTOR signaling in polycystic kidney disease. Trends Mol Med 2011; 17: 625\u201333","DOI":"10.1016\/j.molmed.2011.06.003"},{"key":"10.3238\/arztebl.2015.0884_ref14","doi-asserted-by":"crossref","unstructured":"Harris PC, Torres VE: Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 2014; 124: 2315\u201324 CrossRef","DOI":"10.1172\/JCI72272"},{"key":"10.3238\/arztebl.2015.0884_ref15","doi-asserted-by":"crossref","unstructured":"Mangoo-Karim R, Uchic M, Lechene C, Grantham JJ: Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP. Proc Natl Acad Sci USA 1989; 86: 6007\u201311","DOI":"10.1073\/pnas.86.15.6007"},{"key":"10.3238\/arztebl.2015.0884_ref16","doi-asserted-by":"crossref","unstructured":"Perico N, Antiga L, Caroli A, et al.: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031\u201340","DOI":"10.1681\/ASN.2009121302"},{"key":"10.3238\/arztebl.2015.0884_ref17","doi-asserted-by":"crossref","unstructured":"Serra AL, Poster D, Kistler AD, et al.: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820\u20139","DOI":"10.1056\/NEJMoa0907419"},{"key":"10.3238\/arztebl.2015.0884_ref18","doi-asserted-by":"crossref","unstructured":"Walz G, Budde K, Mannaa M, et al.: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830\u201340","DOI":"10.1056\/NEJMoa1003491"},{"key":"10.3238\/arztebl.2015.0884_ref19","doi-asserted-by":"crossref","unstructured":"Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR: Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol 2014; 9: 881\u20138","DOI":"10.2215\/CJN.02650313"},{"key":"10.3238\/arztebl.2015.0884_ref20","doi-asserted-by":"crossref","unstructured":"Grahammer F, Haenisch N, Steinhardt F, et al.: mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress. Proc Natl Acad Sci U S A 2014; 111: E2817\u201326","DOI":"10.1073\/pnas.1402352111"},{"key":"10.3238\/arztebl.2015.0884_ref21","doi-asserted-by":"crossref","unstructured":"Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846\u201351","DOI":"10.1681\/ASN.2004121090"},{"key":"10.3238\/arztebl.2015.0884_ref22","doi-asserted-by":"crossref","unstructured":"Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363\u20134","DOI":"10.1038\/nm1004"},{"key":"10.3238\/arztebl.2015.0884_ref23","doi-asserted-by":"crossref","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323\u20136","DOI":"10.1038\/nm935"},{"key":"10.3238\/arztebl.2015.0884_ref24","doi-asserted-by":"crossref","unstructured":"Torres VE, Chapman AB, Devuyst O, et al.: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407\u201318","DOI":"10.1056\/NEJMoa1205511"},{"key":"10.3238\/arztebl.2015.0884_ref25","unstructured":"FDA: Briefing Document. Cardiovascular and Renal Drug Advisory Committee Meeting 2013. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM363343.pdf (last accessed on 16 October 2015)."},{"key":"10.3238\/arztebl.2015.0884_ref26","doi-asserted-by":"crossref","unstructured":"Erickson KF, Chertow GM, Goldhaber-Fiebert JD: Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013; 159: 382\u20139","DOI":"10.7326\/0003-4819-159-6-201309170-00004"},{"key":"10.3238\/arztebl.2015.0884_ref27","doi-asserted-by":"crossref","unstructured":"Spithoven EM, Kramer A, Meijer E, et al.: Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 2014; 29: 15\u201325","DOI":"10.1093\/ndt\/gfu017"},{"key":"10.3238\/arztebl.2015.0884_ref28","doi-asserted-by":"crossref","unstructured":"Caroli A, Perico N, Perna A, et al.: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013; 382: 1485\u201395","DOI":"10.1016\/S0140-6736(13)61407-5"},{"key":"10.3238\/arztebl.2015.0884_ref29","doi-asserted-by":"crossref","unstructured":"Cadnapaphornchai MA, George DM, McFann K, et al.: Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2014; 9: 889\u201396","DOI":"10.2215\/CJN.08350813"},{"key":"10.3238\/arztebl.2015.0884_ref30","doi-asserted-by":"crossref","unstructured":"Schrier RW, Abebe KZ, Perrone RD, et al.: Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 2014; 371: 2255\u201366","DOI":"10.1056\/NEJMoa1402685"},{"key":"10.3238\/arztebl.2015.0884_ref31","doi-asserted-by":"crossref","unstructured":"Torres VE, Abebe KZ, Chapman AB, et al.: Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 2014; 371: 2267\u201376","DOI":"10.1056\/NEJMoa1402686"},{"key":"10.3238\/arztebl.2015.0884_ref32","doi-asserted-by":"crossref","unstructured":"Helal I, Reed B, McFann K, et al.: Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2439\u201343","DOI":"10.2215\/CJN.01010211"},{"key":"10.3238\/arztebl.2015.0884_ref33","doi-asserted-by":"crossref","unstructured":"Rossetti S, Consugar MB, Chapman AB, et al.: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143\u201360","DOI":"10.1681\/ASN.2006121387"},{"key":"10.3238\/arztebl.2015.0884_ref34","doi-asserted-by":"crossref","unstructured":"Wheeler DC, Becker GJ: Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 2013; 83: 377\u201383","DOI":"10.1038\/ki.2012.425"},{"key":"10.3238\/arztebl.2015.0884_ref35","doi-asserted-by":"crossref","unstructured":"Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S: Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007; 47: 1498\u2013507","DOI":"10.1177\/0091270007307877"},{"key":"10.3238\/arztebl.2015.0884_ref36","doi-asserted-by":"crossref","unstructured":"Sarnak MJ, Greene T, Wang X, et al.: The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342\u201351","DOI":"10.7326\/0003-4819-142-5-200503010-00009"},{"key":"10.3238\/arztebl.2015.0884_ref37","doi-asserted-by":"crossref","unstructured":"Torres VE, Grantham JJ, Chapman AB, et al.: Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640\u20137","DOI":"10.2215\/CJN.03250410"},{"key":"10.3238\/arztebl.2015.0884_ref38","doi-asserted-by":"crossref","unstructured":"Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF: Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev 2015; 7: CD010294","DOI":"10.1002\/14651858.CD010294.pub2"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:22:06Z","timestamp":1638800526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,21]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0884","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,21]]}}}